COCP - Latest News
Cocrystal Pharma, Inc. (COCP), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $11.5M. Beta to the broader market is 1.50.
The article list below shows the most recent COCP headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent COCP Headlines
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
globenewswire.com - May 26, 2026
Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influ
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
globenewswire.com - May 15, 2026
BOTHELL, Wash. , May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
globenewswire.com - Apr 30, 2026
BOTHELL, Wash. , April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988
benzinga.com - Apr 2, 2026
The company said the FDA's Fast Track designation is intended to facilitate development and expedite regulatory review for drugs that treat serious co
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
globenewswire.com - Apr 2, 2026
FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million glob
How News Affects COCP Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track COCP's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked COCP news questions
- What is the latest COCP news headline?
- The most recent COCP headline (May 26, 2026) is "Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the COCP news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What COCP news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual COCP options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.